Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder, Overactive | 39 | 2021 | 90 | 8.920 |
Why?
|
Urinary Incontinence, Stress | 53 | 2023 | 196 | 7.780 |
Why?
|
Urinary Incontinence | 53 | 2020 | 211 | 6.580 |
Why?
|
Muscarinic Antagonists | 25 | 2012 | 58 | 5.310 |
Why?
|
Mandelic Acids | 20 | 2013 | 20 | 3.800 |
Why?
|
Vagina | 18 | 2022 | 165 | 3.590 |
Why?
|
Uterine Prolapse | 15 | 2022 | 80 | 3.170 |
Why?
|
Cystitis, Interstitial | 12 | 2023 | 53 | 2.780 |
Why?
|
Pelvic Floor | 19 | 2022 | 85 | 2.680 |
Why?
|
Urethra | 21 | 2023 | 115 | 2.540 |
Why?
|
Urinary Incontinence, Urge | 11 | 2021 | 43 | 2.470 |
Why?
|
Urinary Bladder Diseases | 13 | 2012 | 41 | 2.380 |
Why?
|
Pelvic Organ Prolapse | 9 | 2022 | 147 | 2.310 |
Why?
|
Surgical Mesh | 10 | 2022 | 120 | 2.260 |
Why?
|
Quality of Life | 29 | 2021 | 1638 | 2.240 |
Why?
|
Urodynamics | 36 | 2023 | 122 | 2.220 |
Why?
|
Wound Healing | 7 | 2012 | 348 | 2.020 |
Why?
|
Benzhydryl Compounds | 11 | 2012 | 43 | 1.980 |
Why?
|
Electric Stimulation Therapy | 13 | 2021 | 44 | 1.970 |
Why?
|
Female | 192 | 2023 | 45399 | 1.890 |
Why?
|
Nortropanes | 9 | 2011 | 10 | 1.860 |
Why?
|
Surveys and Questionnaires | 25 | 2020 | 2574 | 1.810 |
Why?
|
Urologic Surgical Procedures | 11 | 2018 | 147 | 1.750 |
Why?
|
Gynecologic Surgical Procedures | 9 | 2019 | 142 | 1.690 |
Why?
|
Treatment Outcome | 64 | 2023 | 8104 | 1.480 |
Why?
|
Urinary Bladder | 22 | 2023 | 246 | 1.470 |
Why?
|
Middle Aged | 118 | 2021 | 25477 | 1.450 |
Why?
|
Aged | 99 | 2020 | 18750 | 1.420 |
Why?
|
Humans | 203 | 2023 | 87949 | 1.340 |
Why?
|
Delivery, Obstetric | 10 | 2018 | 117 | 1.310 |
Why?
|
Fecal Incontinence | 8 | 2014 | 57 | 1.210 |
Why?
|
Patient Satisfaction | 8 | 2018 | 458 | 1.190 |
Why?
|
Urology | 11 | 2016 | 117 | 1.120 |
Why?
|
Skin | 4 | 2012 | 570 | 1.090 |
Why?
|
Terminology as Topic | 10 | 2011 | 219 | 1.090 |
Why?
|
Prostheses and Implants | 8 | 2011 | 122 | 1.010 |
Why?
|
Nocturia | 4 | 2023 | 19 | 1.010 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 3 | 2019 | 14 | 1.000 |
Why?
|
Suburethral Slings | 6 | 2018 | 75 | 0.980 |
Why?
|
Pentosan Sulfuric Polyester | 5 | 2008 | 7 | 0.960 |
Why?
|
Dimethyl Sulfoxide | 5 | 2023 | 38 | 0.940 |
Why?
|
Cresols | 9 | 2009 | 17 | 0.930 |
Why?
|
Ligaments | 4 | 2017 | 33 | 0.900 |
Why?
|
Phenylpropanolamine | 8 | 2009 | 15 | 0.890 |
Why?
|
Botulinum Toxins, Type A | 7 | 2018 | 49 | 0.860 |
Why?
|
Menopause | 3 | 2012 | 75 | 0.840 |
Why?
|
Skin Transplantation | 2 | 2020 | 180 | 0.830 |
Why?
|
Transforming Growth Factor beta1 | 2 | 2012 | 88 | 0.820 |
Why?
|
Double-Blind Method | 24 | 2013 | 1711 | 0.790 |
Why?
|
Implantable Neurostimulators | 1 | 2021 | 12 | 0.780 |
Why?
|
Pelvic Floor Disorders | 4 | 2014 | 55 | 0.780 |
Why?
|
Parasympatholytics | 3 | 2009 | 19 | 0.780 |
Why?
|
Adult | 76 | 2019 | 26131 | 0.770 |
Why?
|
Sexuality | 2 | 2014 | 41 | 0.770 |
Why?
|
Aged, 80 and over | 36 | 2018 | 6655 | 0.760 |
Why?
|
Urologic Diseases | 5 | 2013 | 45 | 0.760 |
Why?
|
Cystoscopy | 7 | 2008 | 39 | 0.730 |
Why?
|
Pregnancy, Multiple | 3 | 2005 | 37 | 0.720 |
Why?
|
Collagen | 5 | 2007 | 277 | 0.710 |
Why?
|
Urination Disorders | 7 | 2004 | 50 | 0.690 |
Why?
|
Diabetes Mellitus, Type 1 | 3 | 2014 | 561 | 0.670 |
Why?
|
Suture Techniques | 4 | 2017 | 138 | 0.670 |
Why?
|
Postoperative Complications | 14 | 2011 | 2246 | 0.670 |
Why?
|
Prospective Studies | 28 | 2023 | 4247 | 0.660 |
Why?
|
Urinary Catheterization | 4 | 2004 | 36 | 0.630 |
Why?
|
Follow-Up Studies | 22 | 2019 | 3650 | 0.630 |
Why?
|
Counseling | 2 | 2018 | 159 | 0.630 |
Why?
|
Triamcinolone | 3 | 2023 | 18 | 0.620 |
Why?
|
Pregnancy Complications | 3 | 2018 | 343 | 0.620 |
Why?
|
Tibial Nerve | 5 | 2021 | 14 | 0.620 |
Why?
|
Pelvic Pain | 4 | 2008 | 82 | 0.610 |
Why?
|
Rabbits | 7 | 2012 | 640 | 0.600 |
Why?
|
Retrospective Studies | 26 | 2018 | 8780 | 0.590 |
Why?
|
Ovariectomy | 3 | 2012 | 81 | 0.580 |
Why?
|
Cholinergic Antagonists | 6 | 2019 | 26 | 0.560 |
Why?
|
Pain, Postoperative | 2 | 2017 | 247 | 0.560 |
Why?
|
Cesarean Section | 5 | 2018 | 139 | 0.540 |
Why?
|
Anti-Inflammatory Agents | 4 | 2017 | 342 | 0.540 |
Why?
|
Women's Health | 4 | 2010 | 102 | 0.540 |
Why?
|
Colpotomy | 2 | 2012 | 4 | 0.520 |
Why?
|
Benzilates | 9 | 2011 | 9 | 0.520 |
Why?
|
International Cooperation | 6 | 2010 | 123 | 0.510 |
Why?
|
Urethral Diseases | 3 | 2006 | 15 | 0.510 |
Why?
|
Neuromuscular Agents | 4 | 2016 | 25 | 0.510 |
Why?
|
Recurrence | 12 | 2020 | 1168 | 0.500 |
Why?
|
Magnetics | 4 | 2003 | 41 | 0.500 |
Why?
|
Administration, Cutaneous | 9 | 2013 | 60 | 0.500 |
Why?
|
Communication | 1 | 2018 | 448 | 0.490 |
Why?
|
Tetrahydroisoquinolines | 3 | 2009 | 4 | 0.480 |
Why?
|
Pain | 4 | 2023 | 395 | 0.480 |
Why?
|
Pregnancy | 17 | 2023 | 2974 | 0.470 |
Why?
|
Male | 49 | 2021 | 41697 | 0.470 |
Why?
|
Durapatite | 2 | 2011 | 28 | 0.470 |
Why?
|
Vesico-Ureteral Reflux | 1 | 2014 | 28 | 0.470 |
Why?
|
Quinuclidines | 3 | 2009 | 26 | 0.470 |
Why?
|
Delayed-Action Preparations | 11 | 2011 | 111 | 0.460 |
Why?
|
Rectocele | 2 | 2005 | 7 | 0.450 |
Why?
|
Models, Economic | 1 | 2013 | 60 | 0.450 |
Why?
|
Antidiuretic Agents | 1 | 2013 | 3 | 0.450 |
Why?
|
Female Urogenital Diseases | 2 | 2010 | 10 | 0.450 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2013 | 12 | 0.440 |
Why?
|
Time Factors | 15 | 2021 | 5284 | 0.440 |
Why?
|
Uterus | 1 | 2014 | 217 | 0.440 |
Why?
|
Symptom Assessment | 1 | 2013 | 65 | 0.440 |
Why?
|
Safety | 2 | 2012 | 151 | 0.440 |
Why?
|
Family Health | 1 | 2013 | 162 | 0.430 |
Why?
|
Severity of Illness Index | 11 | 2013 | 1827 | 0.430 |
Why?
|
Lower Urinary Tract Symptoms | 1 | 2013 | 65 | 0.430 |
Why?
|
Cohort Studies | 12 | 2018 | 2802 | 0.420 |
Why?
|
Societies, Medical | 4 | 2010 | 558 | 0.420 |
Why?
|
Sutures | 2 | 2011 | 53 | 0.420 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2012 | 29 | 0.420 |
Why?
|
Cross-Sectional Studies | 7 | 2023 | 1682 | 0.410 |
Why?
|
Drug Administration Schedule | 12 | 2013 | 900 | 0.400 |
Why?
|
Granuloma, Foreign-Body | 1 | 2011 | 6 | 0.400 |
Why?
|
Syringes | 2 | 2002 | 13 | 0.390 |
Why?
|
Rectal Fistula | 1 | 2011 | 18 | 0.380 |
Why?
|
Gynecology | 4 | 2016 | 129 | 0.380 |
Why?
|
Multiple Sclerosis | 1 | 2013 | 264 | 0.380 |
Why?
|
Multivariate Analysis | 8 | 2013 | 994 | 0.380 |
Why?
|
Disease Management | 1 | 2013 | 328 | 0.380 |
Why?
|
Pressure | 8 | 2006 | 166 | 0.380 |
Why?
|
Pelvis | 3 | 2005 | 94 | 0.370 |
Why?
|
Reoperation | 6 | 2020 | 605 | 0.370 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2013 | 1939 | 0.350 |
Why?
|
Biocompatible Materials | 1 | 2011 | 196 | 0.350 |
Why?
|
Tartrates | 3 | 2004 | 6 | 0.350 |
Why?
|
Abdomen | 4 | 2007 | 121 | 0.350 |
Why?
|
Adolescent | 22 | 2021 | 9111 | 0.350 |
Why?
|
Dermis | 2 | 2009 | 27 | 0.340 |
Why?
|
Administration, Intravesical | 5 | 2023 | 33 | 0.340 |
Why?
|
Craniosynostoses | 2 | 2021 | 77 | 0.340 |
Why?
|
Urinary Retention | 3 | 2016 | 42 | 0.340 |
Why?
|
Self Report | 2 | 2021 | 294 | 0.340 |
Why?
|
Tolterodine Tartrate | 8 | 2009 | 15 | 0.330 |
Why?
|
Work | 1 | 2009 | 16 | 0.330 |
Why?
|
Recovery of Function | 1 | 2010 | 287 | 0.330 |
Why?
|
Efficiency | 1 | 2009 | 40 | 0.330 |
Why?
|
Estrogens | 3 | 2023 | 201 | 0.320 |
Why?
|
Developmental Disabilities | 2 | 2021 | 201 | 0.320 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2008 | 47 | 0.310 |
Why?
|
Narcotics | 1 | 2008 | 69 | 0.310 |
Why?
|
Probability | 8 | 2008 | 356 | 0.300 |
Why?
|
Twins, Monozygotic | 4 | 2010 | 57 | 0.300 |
Why?
|
Granulation Tissue | 1 | 2007 | 15 | 0.290 |
Why?
|
Risk Assessment | 10 | 2019 | 2274 | 0.290 |
Why?
|
Surgical Tape | 1 | 2006 | 4 | 0.290 |
Why?
|
Injections | 2 | 2005 | 114 | 0.280 |
Why?
|
Urological Agents | 2 | 2018 | 5 | 0.280 |
Why?
|
Wounds, Penetrating | 1 | 2007 | 46 | 0.280 |
Why?
|
Constipation | 5 | 2010 | 63 | 0.280 |
Why?
|
Hematuria | 3 | 2008 | 51 | 0.270 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2008 | 168 | 0.270 |
Why?
|
Risk Factors | 12 | 2013 | 5405 | 0.270 |
Why?
|
Age Factors | 8 | 2012 | 1853 | 0.260 |
Why?
|
Reproducibility of Results | 7 | 2013 | 2740 | 0.260 |
Why?
|
Medication Adherence | 2 | 2018 | 133 | 0.260 |
Why?
|
Postoperative Care | 2 | 2004 | 224 | 0.260 |
Why?
|
Intrauterine Devices | 1 | 2005 | 28 | 0.260 |
Why?
|
Fascia Lata | 1 | 2005 | 7 | 0.260 |
Why?
|
Dehydration | 1 | 2005 | 18 | 0.260 |
Why?
|
Gels | 5 | 2013 | 49 | 0.260 |
Why?
|
Logistic Models | 6 | 2008 | 1200 | 0.260 |
Why?
|
Colposcopy | 1 | 2005 | 16 | 0.260 |
Why?
|
Dyspareunia | 1 | 2005 | 19 | 0.250 |
Why?
|
Solvents | 1 | 2005 | 96 | 0.250 |
Why?
|
Sweden | 3 | 2014 | 40 | 0.250 |
Why?
|
Psychometrics | 5 | 2014 | 328 | 0.250 |
Why?
|
Surgical Procedures, Operative | 1 | 2007 | 190 | 0.240 |
Why?
|
Cystitis | 1 | 2004 | 13 | 0.240 |
Why?
|
Equipment Design | 2 | 2021 | 415 | 0.240 |
Why?
|
Urinary Tract Infections | 3 | 2021 | 74 | 0.240 |
Why?
|
Anal Canal | 3 | 2011 | 89 | 0.240 |
Why?
|
Elective Surgical Procedures | 1 | 2005 | 117 | 0.240 |
Why?
|
Sexual Dysfunction, Physiological | 3 | 2013 | 69 | 0.230 |
Why?
|
Transplantation, Heterologous | 1 | 2005 | 370 | 0.230 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2008 | 392 | 0.230 |
Why?
|
Eosinophilia | 1 | 2004 | 85 | 0.230 |
Why?
|
Exercise Therapy | 2 | 2002 | 80 | 0.230 |
Why?
|
Delivery of Health Care | 1 | 2008 | 432 | 0.230 |
Why?
|
Urination | 5 | 2012 | 37 | 0.220 |
Why?
|
Puerperal Disorders | 1 | 2003 | 32 | 0.220 |
Why?
|
Prevalence | 4 | 2014 | 1247 | 0.220 |
Why?
|
Muscle Contraction | 4 | 2014 | 284 | 0.220 |
Why?
|
Administration, Oral | 6 | 2013 | 680 | 0.220 |
Why?
|
Parity | 5 | 2011 | 94 | 0.220 |
Why?
|
Allografts | 2 | 2020 | 174 | 0.210 |
Why?
|
Bupivacaine | 3 | 2023 | 45 | 0.210 |
Why?
|
Random Allocation | 3 | 2012 | 329 | 0.210 |
Why?
|
Feasibility Studies | 3 | 2021 | 769 | 0.210 |
Why?
|
Reference Values | 7 | 2013 | 665 | 0.210 |
Why?
|
Mothers | 1 | 2003 | 143 | 0.210 |
Why?
|
Predictive Value of Tests | 10 | 2012 | 1697 | 0.200 |
Why?
|
Polyglactin 910 | 1 | 2001 | 5 | 0.200 |
Why?
|
Prosthesis Implantation | 2 | 2021 | 126 | 0.200 |
Why?
|
Trimethoprim | 1 | 2021 | 15 | 0.200 |
Why?
|
Drug Therapy, Combination | 4 | 2017 | 795 | 0.200 |
Why?
|
Adaptation, Psychological | 2 | 2021 | 162 | 0.190 |
Why?
|
Urogenital Surgical Procedures | 2 | 2011 | 10 | 0.190 |
Why?
|
Glutaral | 1 | 2000 | 5 | 0.190 |
Why?
|
Animals | 9 | 2012 | 27028 | 0.190 |
Why?
|
Heparin | 2 | 2023 | 184 | 0.190 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2008 | 1091 | 0.190 |
Why?
|
Diffusion of Innovation | 1 | 2001 | 71 | 0.180 |
Why?
|
Transplants | 2 | 2011 | 42 | 0.180 |
Why?
|
Epidemiologic Methods | 2 | 2010 | 59 | 0.180 |
Why?
|
Acetylcholine Release Inhibitors | 2 | 2016 | 3 | 0.180 |
Why?
|
Evidence-Based Medicine | 6 | 2011 | 428 | 0.180 |
Why?
|
Incidence | 6 | 2019 | 1580 | 0.170 |
Why?
|
Electric Stimulation | 1 | 2000 | 350 | 0.170 |
Why?
|
Minimally Invasive Surgical Procedures | 3 | 2014 | 242 | 0.170 |
Why?
|
Solifenacin Succinate | 3 | 2009 | 6 | 0.170 |
Why?
|
Urinary Sphincter, Artificial | 1 | 1999 | 14 | 0.170 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2011 | 834 | 0.160 |
Why?
|
Condylomata Acuminata | 3 | 1987 | 15 | 0.160 |
Why?
|
Urinary Tract | 2 | 2013 | 34 | 0.160 |
Why?
|
Syndrome | 3 | 2019 | 446 | 0.160 |
Why?
|
Electrodes, Implanted | 1 | 2019 | 177 | 0.160 |
Why?
|
Cryosurgery | 2 | 1989 | 52 | 0.160 |
Why?
|
Pubic Bone | 3 | 2004 | 9 | 0.160 |
Why?
|
Parturition | 1 | 2018 | 21 | 0.160 |
Why?
|
Secondary Prevention | 3 | 2005 | 162 | 0.150 |
Why?
|
Chronic Disease | 5 | 2010 | 942 | 0.150 |
Why?
|
Observational Studies as Topic | 1 | 2018 | 49 | 0.150 |
Why?
|
Sacrococcygeal Region | 1 | 2017 | 9 | 0.150 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2016 | 520 | 0.150 |
Why?
|
Orthopedic Procedures | 1 | 2019 | 127 | 0.150 |
Why?
|
Pain Measurement | 2 | 2017 | 328 | 0.150 |
Why?
|
Hernia, Ventral | 1 | 1997 | 24 | 0.150 |
Why?
|
Cystostomy | 1 | 1997 | 15 | 0.150 |
Why?
|
Hysterectomy | 2 | 2008 | 150 | 0.140 |
Why?
|
Vulvar Diseases | 2 | 2008 | 8 | 0.140 |
Why?
|
Odds Ratio | 5 | 2008 | 682 | 0.140 |
Why?
|
Case-Control Studies | 3 | 2018 | 1843 | 0.130 |
Why?
|
Clinical Trials as Topic | 2 | 2013 | 1141 | 0.130 |
Why?
|
Illinois | 1 | 2017 | 465 | 0.130 |
Why?
|
Ultrasonography | 3 | 2018 | 703 | 0.130 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 1998 | 242 | 0.130 |
Why?
|
Lumbosacral Plexus | 2 | 2005 | 9 | 0.130 |
Why?
|
Combined Modality Therapy | 2 | 2010 | 1703 | 0.130 |
Why?
|
Cystocele | 2 | 2019 | 7 | 0.130 |
Why?
|
Child | 5 | 2021 | 7065 | 0.130 |
Why?
|
Postoperative Period | 3 | 2006 | 307 | 0.130 |
Why?
|
Young Adult | 8 | 2018 | 6151 | 0.130 |
Why?
|
Xerostomia | 3 | 2004 | 10 | 0.130 |
Why?
|
Prolapse | 2 | 2005 | 10 | 0.130 |
Why?
|
Anatomic Landmarks | 1 | 2014 | 30 | 0.120 |
Why?
|
Diagnosis, Differential | 2 | 2010 | 1586 | 0.120 |
Why?
|
Compliance | 1 | 2014 | 20 | 0.120 |
Why?
|
Urinary Bladder, Neurogenic | 2 | 2001 | 25 | 0.120 |
Why?
|
Analysis of Variance | 4 | 2004 | 901 | 0.120 |
Why?
|
Physician-Patient Relations | 2 | 2018 | 617 | 0.120 |
Why?
|
Longitudinal Studies | 1 | 2018 | 1037 | 0.120 |
Why?
|
Surgeons | 1 | 2018 | 242 | 0.120 |
Why?
|
Muscles | 2 | 1991 | 193 | 0.110 |
Why?
|
Diagnostic Techniques, Urological | 1 | 2013 | 13 | 0.110 |
Why?
|
Medication Therapy Management | 1 | 2013 | 15 | 0.110 |
Why?
|
Diabetes Complications | 1 | 2014 | 172 | 0.110 |
Why?
|
Patient Safety | 2 | 2013 | 215 | 0.110 |
Why?
|
Drug Administration Routes | 1 | 2012 | 19 | 0.110 |
Why?
|
Patient Compliance | 2 | 2012 | 228 | 0.110 |
Why?
|
Internal Medicine | 1 | 2016 | 356 | 0.110 |
Why?
|
Evaluation Studies as Topic | 3 | 2007 | 271 | 0.100 |
Why?
|
Sex Factors | 2 | 2012 | 1059 | 0.100 |
Why?
|
Confidence Intervals | 3 | 2004 | 225 | 0.100 |
Why?
|
Osteomyelitis | 2 | 2004 | 54 | 0.100 |
Why?
|
United States | 9 | 2012 | 6809 | 0.100 |
Why?
|
Biofeedback, Psychology | 2 | 2007 | 13 | 0.100 |
Why?
|
Health Status Indicators | 1 | 2012 | 104 | 0.100 |
Why?
|
Medical History Taking | 2 | 2008 | 80 | 0.100 |
Why?
|
Age Distribution | 1 | 2012 | 200 | 0.100 |
Why?
|
Equipment Reuse | 2 | 2002 | 7 | 0.100 |
Why?
|
Injections, Intramuscular | 3 | 2016 | 63 | 0.100 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2012 | 281 | 0.100 |
Why?
|
Internship and Residency | 1 | 2001 | 1036 | 0.100 |
Why?
|
Prosthesis Failure | 1 | 2011 | 113 | 0.100 |
Why?
|
Cognition | 3 | 2021 | 577 | 0.100 |
Why?
|
Electromagnetic Phenomena | 2 | 2001 | 18 | 0.100 |
Why?
|
Risk | 4 | 2006 | 660 | 0.100 |
Why?
|
Diverticulum | 1 | 2011 | 45 | 0.100 |
Why?
|
Perineum | 1 | 2011 | 36 | 0.100 |
Why?
|
Cost Savings | 2 | 2002 | 69 | 0.100 |
Why?
|
Polytetrafluoroethylene | 1 | 2011 | 74 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 2 | 2018 | 3425 | 0.090 |
Why?
|
Depression | 1 | 2014 | 492 | 0.090 |
Why?
|
Placebos | 1 | 2011 | 213 | 0.090 |
Why?
|
Abscess | 1 | 2011 | 94 | 0.090 |
Why?
|
Vancomycin | 1 | 2011 | 73 | 0.090 |
Why?
|
Drug Interactions | 1 | 2011 | 248 | 0.090 |
Why?
|
Rectum | 2 | 2010 | 148 | 0.090 |
Why?
|
Blood Glucose | 1 | 2014 | 839 | 0.090 |
Why?
|
Physical Examination | 2 | 2010 | 148 | 0.090 |
Why?
|
Intelligence Tests | 2 | 2021 | 38 | 0.090 |
Why?
|
Abdominal Pain | 2 | 2004 | 139 | 0.090 |
Why?
|
Sickness Impact Profile | 1 | 2009 | 27 | 0.090 |
Why?
|
Cost of Illness | 2 | 2012 | 147 | 0.090 |
Why?
|
Radiography | 2 | 2005 | 810 | 0.090 |
Why?
|
Up-Regulation | 1 | 2012 | 726 | 0.090 |
Why?
|
Muscle, Smooth | 2 | 2002 | 354 | 0.090 |
Why?
|
Biomarkers | 2 | 2014 | 1744 | 0.090 |
Why?
|
Device Removal | 1 | 2011 | 167 | 0.080 |
Why?
|
Methotrexate | 2 | 1986 | 250 | 0.080 |
Why?
|
Equipment Failure | 2 | 2006 | 120 | 0.080 |
Why?
|
Tensile Strength | 2 | 2006 | 80 | 0.080 |
Why?
|
Child, Preschool | 2 | 2014 | 3661 | 0.080 |
Why?
|
Hydroxyzine | 1 | 2008 | 7 | 0.080 |
Why?
|
Amitriptyline | 1 | 2008 | 11 | 0.080 |
Why?
|
Multicenter Studies as Topic | 1 | 2009 | 155 | 0.080 |
Why?
|
Therapeutic Irrigation | 1 | 2008 | 61 | 0.080 |
Why?
|
Histamine H1 Antagonists | 1 | 2008 | 40 | 0.080 |
Why?
|
Medical Audit | 1 | 2008 | 39 | 0.080 |
Why?
|
Muscle Hypotonia | 1 | 1988 | 45 | 0.080 |
Why?
|
Diseases in Twins | 1 | 2008 | 65 | 0.080 |
Why?
|
Office Visits | 1 | 2008 | 50 | 0.080 |
Why?
|
Health Surveys | 4 | 2012 | 239 | 0.080 |
Why?
|
Child Behavior | 2 | 2021 | 48 | 0.080 |
Why?
|
Periodicals as Topic | 1 | 2009 | 168 | 0.070 |
Why?
|
Analgesics | 1 | 2008 | 119 | 0.070 |
Why?
|
Urethral Neoplasms | 1 | 1987 | 10 | 0.070 |
Why?
|
Libido | 1 | 2006 | 8 | 0.070 |
Why?
|
Preoperative Care | 2 | 2005 | 399 | 0.070 |
Why?
|
Length of Stay | 2 | 2000 | 716 | 0.070 |
Why?
|
Marriage | 1 | 2006 | 25 | 0.070 |
Why?
|
Trophoblasts | 1 | 1986 | 33 | 0.070 |
Why?
|
Elasticity | 1 | 2006 | 95 | 0.070 |
Why?
|
RNA, Messenger | 1 | 2012 | 1996 | 0.070 |
Why?
|
Equipment Safety | 1 | 2005 | 33 | 0.070 |
Why?
|
Muscle Strength | 1 | 2005 | 30 | 0.070 |
Why?
|
Uterine Neoplasms | 3 | 1986 | 236 | 0.070 |
Why?
|
Organizations | 3 | 2010 | 17 | 0.070 |
Why?
|
Forecasting | 1 | 2007 | 304 | 0.070 |
Why?
|
Family Practice | 1 | 2006 | 85 | 0.070 |
Why?
|
Cyanates | 1 | 2005 | 1 | 0.070 |
Why?
|
Vulvitis | 1 | 2005 | 2 | 0.070 |
Why?
|
Clobetasol | 1 | 2005 | 3 | 0.070 |
Why?
|
Foreign-Body Reaction | 1 | 2005 | 11 | 0.060 |
Why?
|
Demography | 1 | 2005 | 179 | 0.060 |
Why?
|
Nerve Block | 1 | 2005 | 50 | 0.060 |
Why?
|
Cross-Linking Reagents | 1 | 2005 | 86 | 0.060 |
Why?
|
Benzofurans | 1 | 2004 | 8 | 0.060 |
Why?
|
Valsalva Maneuver | 1 | 2004 | 6 | 0.060 |
Why?
|
Life Tables | 1 | 2004 | 48 | 0.060 |
Why?
|
Cadaver | 2 | 2004 | 185 | 0.060 |
Why?
|
Actinomycosis | 1 | 2004 | 12 | 0.060 |
Why?
|
Central Nervous System | 1 | 2005 | 152 | 0.060 |
Why?
|
Trophoblastic Neoplasms | 1 | 1984 | 5 | 0.060 |
Why?
|
Receptor, Cholecystokinin B | 1 | 2004 | 3 | 0.060 |
Why?
|
Pyrrolidines | 1 | 2004 | 59 | 0.060 |
Why?
|
Cholecystokinin | 1 | 2004 | 15 | 0.060 |
Why?
|
Vision Disorders | 1 | 2004 | 75 | 0.060 |
Why?
|
Genital Diseases, Female | 1 | 2004 | 24 | 0.060 |
Why?
|
Triplets | 1 | 2003 | 8 | 0.060 |
Why?
|
Panic Disorder | 1 | 2004 | 21 | 0.060 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 1984 | 27 | 0.060 |
Why?
|
Electromyography | 1 | 2004 | 192 | 0.060 |
Why?
|
Twins | 1 | 2003 | 65 | 0.060 |
Why?
|
Salivation | 1 | 2003 | 3 | 0.060 |
Why?
|
Northwestern United States | 1 | 2003 | 7 | 0.060 |
Why?
|
Swine | 1 | 2005 | 577 | 0.060 |
Why?
|
Obesity | 1 | 2010 | 957 | 0.060 |
Why?
|
Sexual Behavior | 1 | 2006 | 307 | 0.060 |
Why?
|
Indigo Carmine | 1 | 2002 | 3 | 0.060 |
Why?
|
Self Care | 1 | 2004 | 164 | 0.050 |
Why?
|
Coloring Agents | 1 | 2002 | 65 | 0.050 |
Why?
|
Congresses as Topic | 1 | 2003 | 112 | 0.050 |
Why?
|
Bioprosthesis | 1 | 2002 | 36 | 0.050 |
Why?
|
Transducers, Pressure | 1 | 2001 | 6 | 0.050 |
Why?
|
Methods | 4 | 1989 | 152 | 0.050 |
Why?
|
Hippurates | 1 | 2021 | 3 | 0.050 |
Why?
|
Methenamine | 1 | 2021 | 3 | 0.050 |
Why?
|
Fiber Optic Technology | 1 | 2001 | 35 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2008 | 1024 | 0.050 |
Why?
|
Intraoperative Complications | 1 | 2002 | 188 | 0.050 |
Why?
|
Fasciotomy | 1 | 2000 | 16 | 0.050 |
Why?
|
Adolescent Development | 1 | 2021 | 21 | 0.050 |
Why?
|
Fasciitis, Necrotizing | 1 | 2000 | 12 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 1996 | 2019 | 0.050 |
Why?
|
Substance-Related Disorders | 2 | 1996 | 407 | 0.050 |
Why?
|
Parkinson Disease | 1 | 2002 | 142 | 0.050 |
Why?
|
Polymorphism, Genetic | 1 | 2004 | 825 | 0.040 |
Why?
|
Adolescent Behavior | 1 | 2021 | 108 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2007 | 2317 | 0.040 |
Why?
|
Time-to-Treatment | 1 | 2021 | 104 | 0.040 |
Why?
|
Bone Screws | 1 | 1999 | 45 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2012 | 271 | 0.040 |
Why?
|
Nickel | 1 | 2019 | 13 | 0.040 |
Why?
|
Incontinence Pads | 1 | 1999 | 4 | 0.040 |
Why?
|
Posture | 2 | 1991 | 124 | 0.040 |
Why?
|
Child Development | 1 | 2021 | 167 | 0.040 |
Why?
|
Bisacodyl | 1 | 1978 | 1 | 0.040 |
Why?
|
Proctitis | 1 | 1978 | 12 | 0.040 |
Why?
|
Patient Selection | 1 | 2002 | 685 | 0.040 |
Why?
|
Enema | 1 | 1978 | 37 | 0.040 |
Why?
|
Sacrum | 1 | 2018 | 43 | 0.040 |
Why?
|
Suppositories | 1 | 1998 | 3 | 0.040 |
Why?
|
Administration, Rectal | 1 | 1998 | 12 | 0.040 |
Why?
|
Bacterial Infections | 1 | 1999 | 184 | 0.040 |
Why?
|
Behavior Therapy | 2 | 1990 | 83 | 0.040 |
Why?
|
Phosphates | 1 | 1978 | 159 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 1984 | 1347 | 0.040 |
Why?
|
Choriocarcinoma | 3 | 1986 | 7 | 0.040 |
Why?
|
Urinalysis | 1 | 1997 | 31 | 0.040 |
Why?
|
General Practice | 1 | 2016 | 9 | 0.040 |
Why?
|
Patient Reported Outcome Measures | 1 | 2018 | 186 | 0.040 |
Why?
|
Supine Position | 1 | 1996 | 30 | 0.040 |
Why?
|
Fluocortolone | 1 | 1996 | 1 | 0.030 |
Why?
|
Retinitis | 1 | 1996 | 3 | 0.030 |
Why?
|
Curriculum | 1 | 2001 | 556 | 0.030 |
Why?
|
Methylprednisolone | 1 | 1996 | 66 | 0.030 |
Why?
|
Urologic Neoplasms | 1 | 1997 | 81 | 0.030 |
Why?
|
Uveitis | 1 | 1996 | 30 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1978 | 237 | 0.030 |
Why?
|
Referral and Consultation | 1 | 2018 | 339 | 0.030 |
Why?
|
Stress, Physiological | 1 | 1996 | 231 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2007 | 307 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2001 | 756 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 858 | 0.030 |
Why?
|
Schizophrenia, Paranoid | 1 | 1993 | 4 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 1996 | 506 | 0.030 |
Why?
|
Glucocorticoids | 1 | 1996 | 358 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2001 | 1182 | 0.030 |
Why?
|
Body Mass Index | 2 | 2008 | 765 | 0.030 |
Why?
|
Crime | 1 | 1993 | 36 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 1978 | 800 | 0.030 |
Why?
|
Infant | 1 | 2019 | 3105 | 0.030 |
Why?
|
Schizophrenic Psychology | 1 | 1993 | 133 | 0.030 |
Why?
|
Caregivers | 1 | 2014 | 155 | 0.030 |
Why?
|
Canada | 1 | 2012 | 206 | 0.030 |
Why?
|
ROC Curve | 1 | 1995 | 769 | 0.030 |
Why?
|
Health Status | 1 | 2014 | 366 | 0.030 |
Why?
|
Alcoholism | 1 | 1993 | 174 | 0.030 |
Why?
|
Labor Stage, Second | 1 | 2011 | 6 | 0.030 |
Why?
|
Chorionic Gonadotropin | 3 | 1986 | 72 | 0.030 |
Why?
|
Electrosurgery | 1 | 2011 | 9 | 0.030 |
Why?
|
Cephalometry | 1 | 2011 | 50 | 0.020 |
Why?
|
Prognosis | 2 | 1990 | 3729 | 0.020 |
Why?
|
Violence | 1 | 1993 | 147 | 0.020 |
Why?
|
Kidney | 1 | 1997 | 1140 | 0.020 |
Why?
|
Baths | 1 | 2011 | 8 | 0.020 |
Why?
|
Therapeutic Equivalency | 1 | 2011 | 12 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2011 | 131 | 0.020 |
Why?
|
Sunscreening Agents | 1 | 2011 | 8 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2012 | 207 | 0.020 |
Why?
|
Adrenergic alpha-Agonists | 1 | 1990 | 33 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 1999 | 2624 | 0.020 |
Why?
|
Videotape Recording | 1 | 1990 | 47 | 0.020 |
Why?
|
Fetus | 1 | 2011 | 230 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 333 | 0.020 |
Why?
|
Clinical Protocols | 1 | 1990 | 156 | 0.020 |
Why?
|
Massage | 1 | 1989 | 3 | 0.020 |
Why?
|
Physical Therapy Modalities | 1 | 1990 | 83 | 0.020 |
Why?
|
Mass Screening | 1 | 2014 | 627 | 0.020 |
Why?
|
Dilatation | 1 | 1989 | 48 | 0.020 |
Why?
|
Frail Elderly | 1 | 2010 | 74 | 0.020 |
Why?
|
Polyuria | 1 | 2009 | 7 | 0.020 |
Why?
|
Water | 1 | 2011 | 284 | 0.020 |
Why?
|
Administration, Topical | 1 | 2009 | 96 | 0.020 |
Why?
|
Regression Analysis | 1 | 2010 | 594 | 0.020 |
Why?
|
Algorithms | 1 | 1997 | 1857 | 0.020 |
Why?
|
Consensus | 1 | 2010 | 349 | 0.020 |
Why?
|
Manometry | 1 | 1987 | 44 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 1990 | 354 | 0.020 |
Why?
|
Hydatidiform Mole, Invasive | 2 | 1984 | 2 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2007 | 149 | 0.020 |
Why?
|
Pregnancy, Tubal | 1 | 1986 | 4 | 0.020 |
Why?
|
Cattle | 1 | 2007 | 376 | 0.020 |
Why?
|
Enuresis | 1 | 1986 | 4 | 0.020 |
Why?
|
Twin Studies as Topic | 1 | 2006 | 19 | 0.020 |
Why?
|
Skin Physiological Phenomena | 1 | 2006 | 27 | 0.020 |
Why?
|
Premenopause | 1 | 2006 | 54 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2007 | 390 | 0.020 |
Why?
|
Pregnancy, Ectopic | 1 | 1986 | 36 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 1986 | 506 | 0.020 |
Why?
|
Lasers | 1 | 1986 | 107 | 0.020 |
Why?
|
Focus Groups | 1 | 2006 | 161 | 0.020 |
Why?
|
Postmenopause | 1 | 2006 | 99 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2010 | 476 | 0.020 |
Why?
|
Biomedical Research | 1 | 2010 | 385 | 0.020 |
Why?
|
Vulva | 1 | 2005 | 23 | 0.020 |
Why?
|
Anesthetics, Local | 1 | 2005 | 76 | 0.020 |
Why?
|
Cell Division | 1 | 1986 | 695 | 0.020 |
Why?
|
Shock, Septic | 1 | 1986 | 104 | 0.020 |
Why?
|
Linear Models | 1 | 2006 | 423 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 1986 | 993 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2006 | 179 | 0.020 |
Why?
|
Genital Neoplasms, Female | 1 | 1986 | 108 | 0.020 |
Why?
|
Rectus Abdominis | 1 | 2004 | 40 | 0.010 |
Why?
|
Surgical Instruments | 1 | 2004 | 58 | 0.010 |
Why?
|
Dermatitis, Contact | 1 | 2003 | 6 | 0.010 |
Why?
|
Staphylococcal Infections | 1 | 1986 | 268 | 0.010 |
Why?
|
Headache | 1 | 2003 | 72 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2004 | 333 | 0.010 |
Why?
|
Biopsy | 1 | 1986 | 1181 | 0.010 |
Why?
|
Hydatidiform Mole | 1 | 1982 | 6 | 0.010 |
Why?
|
Diarrhea | 1 | 2003 | 182 | 0.010 |
Why?
|
Gene Frequency | 1 | 2004 | 682 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2005 | 433 | 0.010 |
Why?
|
Electromagnetic Fields | 1 | 2000 | 26 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2002 | 193 | 0.010 |
Why?
|
Suction | 1 | 1999 | 35 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 2001 | 157 | 0.010 |
Why?
|
Debridement | 1 | 1999 | 57 | 0.010 |
Why?
|
Genotype | 1 | 2004 | 1866 | 0.010 |
Why?
|
Genetic Variation | 1 | 2004 | 1366 | 0.010 |
Why?
|
Treatment Refusal | 1 | 1996 | 61 | 0.010 |
Why?
|
Bacteria | 1 | 1999 | 463 | 0.010 |
Why?
|
Depressive Disorder | 1 | 1996 | 223 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 1999 | 765 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 1996 | 491 | 0.010 |
Why?
|
Bipolar Disorder | 1 | 1996 | 384 | 0.010 |
Why?
|
Pregnancy Tests | 1 | 1986 | 2 | 0.000 |
Why?
|
Hysterosalpingography | 1 | 1986 | 7 | 0.000 |
Why?
|
Amenorrhea | 1 | 1986 | 27 | 0.000 |
Why?
|
Hemoperitoneum | 1 | 1986 | 4 | 0.000 |
Why?
|
Uterine Hemorrhage | 1 | 1986 | 20 | 0.000 |
Why?
|
Drug Evaluation | 1 | 1986 | 138 | 0.000 |
Why?
|
Laparoscopy | 1 | 1986 | 761 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1982 | 2436 | 0.000 |
Why?
|